Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

J. Biol. Chem. 279 (29): 30375-30384

© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor*

Terrance G. Johns{ddagger}§¶, Timothy E. Adams§||, Jennifer R. Cochran§**, Nathan E Hall{ddagger}{ddagger}, Peter A. Hoyne||, Mark J. Olsen**, Yong-Sung Kim**, Julie Rothacker{ddagger}{ddagger}, Edouard C. Nice{ddagger}{ddagger}, Francesca Walker{ddagger}{ddagger}, Gerd Ritter§§, Achim A. Jungbluth§§, Lloyd J. Old§§, Colin W. Ward||, Antony W. Burgess{ddagger}{ddagger}, K. Dane Wittrup**, , and Andrew M. Scott{ddagger}

{ddagger}Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg 3084, Australia, ||CSIRO Health Sciences and Nutrition, Parkville 3052, Australia, **Chemical Engineering & Bioengineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, {ddagger}{ddagger}Epithelial Biochemistry Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville 3050, Australia, and §§Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Abstract: The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial cancers, an observation often correlated with poor clinical outcome. Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2–7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. Monoclonal antibody (mAb) 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2–7 EGFR and a subset of the wild type (wt) EGFR when overexpressed but does not bind the wt EGFR expressed in normal tissues. Despite only binding to a low proportion of the wt EGFR expressed in A431 tumor cells (~10%), mAb 806 displays robust antitumor activity against A431 xenografts grown in nude mice. To elucidate the mechanism leading to its unique specificity and mode of antitumor activity, we have determined the EGFR binding epitope of mAb 806. Analysis of mAb 806 binding to EGFR fragments expressed either on the surface of yeast or in an immunoblot format identified a disulfide-bonded loop (amino acids 287–302) that contains the mAb 806 epitope. Indeed, mAb 806 binds with apparent high affinity (~30 nM) to a synthetic EGFR peptide corresponding to these amino acids. Analysis of EGFR structures indicates that the epitope is fully exposed only in the transitional form of the receptor that occurs because EGFR changes from the inactive tethered conformation to a ligand-bound active form. It would seem that mAb 806 binds this small proportion of transient receptors, preventing their activation, which in turn generates a strong antitumor effect. Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity.


Received for publication February 4, 2004. Revision received April 8, 2004.

* This work was supported in part by National Institutes of Health Grant CA96504, the Ludwig Trust, and the National Health and Medical Research Council of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

To whom correspondence should be addressed: Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Hospital, Level 6, Harold Stokes Building, Studley Road, Heidelberg 3084, Australia. Tel.: 613-9496-3068; Fax: 613-9496-5892; E-mail: terry.johns{at}ludwig.edu.au.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy.
H. K. Gan, A. W. Burgess, A. H. A. Clayton, and A. M. Scott (2012)
Cancer Res. 72, 2924-2930
   Abstract »    Full Text »    PDF »
Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
H. Wang, B. Shi, Q. Zhang, H. Jiang, S. Hu, J. Kong, M. Yao, S. Yang, and Z. Li (2012)
FASEB J 26, 73-80
   Abstract »    Full Text »    PDF »
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
A. N. Cvrljevic, D. Akhavan, M. Wu, P. Martinello, F. B. Furnari, A. J. Johnston, D. Guo, L. Pike, W. K. Cavenee, A. M. Scott, et al. (2011)
J. Cell Sci. 124, 2938-2950
   Abstract »    Full Text »    PDF »
Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III.
H. Jiang, H. Wang, Z. Tan, S. Hu, H. Wang, B. Shi, L. Yang, P. Li, J. Gu, H. Wang, et al. (2011)
J. Biol. Chem. 286, 5913-5920
   Abstract »    Full Text »    PDF »
Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806.
F. T. Lee, G. J. O'Keefe, H. K. Gan, A. J. Mountain, G. R. Jones, T. H. Saunder, J. Sagona, A. Rigopoulos, F. E. Smyth, T. G. Johns, et al. (2010)
J. Nucl. Med. 51, 967-972
   Abstract »    Full Text »    PDF »
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
T. P. J. Garrett, A. W. Burgess, H. K. Gan, R. B. Luwor, G. Cartwright, F. Walker, S. G. Orchard, A. H. A. Clayton, E. C. Nice, J. Rothacker, et al. (2009)
PNAS 106, 5082-5087
   Abstract »    Full Text »    PDF »
Mapping ErbB receptors on breast cancer cell membranes during signal transduction.
S. Yang, M. A. Raymond-Stintz, W. Ying, J. Zhang, D. S. Lidke, S. L. Steinberg, L. Williams, J. M. Oliver, and B. S. Wilson (2007)
J. Cell Sci. 120, 2763-2773
   Abstract »    Full Text »    PDF »
Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
M. Friedman, E. Nordberg, I. Hoiden-Guthenberg, H. Brismar, G.P. Adams, F.Y. Nilsson, J. Carlsson, and S. Stahl (2007)
Protein Eng. Des. Sel.
   Abstract »    Full Text »    PDF »
The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization.
T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari (2007)
Clin. Cancer Res. 13, 1911-1925
   Abstract »    Full Text »    PDF »
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
A. M. Scott, F.-T. Lee, N. Tebbutt, R. Herbertson, S. S. Gill, Z. Liu, E. Skrinos, C. Murone, T. H. Saunder, B. Chappell, et al. (2007)
PNAS 104, 4071-4076
   Abstract »    Full Text »    PDF »
The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers: IMPLICATIONS FOR COMBINATION THERAPY WITH MONOCLONAL ANTIBODY 806.
H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott, and T. G. Johns (2007)
J. Biol. Chem. 282, 2840-2850
   Abstract »    Full Text »    PDF »
In Reply:.
M. P. DiGiovanna, D. F. Stern, S. M. Edgerton, and A. D. Thor (2005)
J. Clin. Oncol. 23, 8119-8120
   Full Text »    PDF »
Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity.
R. M. Perera, Y. Narita, F. B. Furnari, H. K. Gan, C. Murone, M. Ahlkvist, R. B. Luwor, A. W. Burgess, E. Stockert, A. A. Jungbluth, et al. (2005)
Clin. Cancer Res. 11, 6390-6399
   Abstract »    Full Text »    PDF »
Comprehensive Antibody Epitope Mapping of the Nucleocapsid Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Insight into the Humoral Immunity of SARS.
Y. Liang, Y. Wan, L.-w. Qiu, J. Zhou, B. Ni, B. Guo, Q. Zou, L. Zou, W. Zhou, Z. Jia, et al. (2005)
Clin. Chem. 51, 1382-1396
   Abstract »    Full Text »    PDF »
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry.
K. Y. Chung, J. Shia, N. E. Kemeny, M. Shah, G. K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, L. Schwartz, et al. (2005)
J. Clin. Oncol. 23, 1803-1810
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882